To evaluate the effect of passive immunization with anticapsular antibodies on nasopharyngeal carriage, two models of Streptococcus pneumoniae colonization were developed in infant rats. In a direct inoculation model, 3-to 4-day-old infant rats were intranasally inoculated with 2 1 10 5 cfu of S. pneumoniae type 3 or 6 1 10 3 cfu of S. pneumoniae type 23F. In an intralitter transmission model, 2 infant rats were intranasally inoculated with 10 3 cfu of pneumococcus type 3 or type 19F and placed in a cage containing 10 infant rats. Pretreatment with bacterial polysaccharide immune globulin led to a significant reduction in colonization of contact animals with S. pneumoniae type 3 or 19F in the intralitter transmission model (P õ .05). No effect of immune globulin could be demonstrated in the direct inoculation model. These results indicate that systemic anticapsular antibodies conferred significant protection against nasopharyngeal acquisition by intralitter spread of S. pneumoniae type 3 and 19F.
The nasopharynx is the main reservoir for polysaccharide after close contact with infected persons, has been shown to be a risk factor for the development of invasive disease. Invaencapsulated bacteria, such as Streptococcus pneumoniae, sive S. pneumoniae disease usually occurs within 1 month of Haemophilus influenzae type b (Hib), and Neisseria meningitacquisition of a new serotype [1] . Immune-mediated prevention idis. Exposure to these organisms, as in day care centers or of nasopharyngeal colonization may therefore lead to an important reduction in the incidence of invasive pneumococcal 
Materials and Methods
assessed daily for 10 days as described above. Anticapsular antibody ELISA. Serum type 19F antipneumoAnimals. Outbred, virus-free pregnant female Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) were alcoccal IgG was measured by ELISA using the method of Quataert et al. [5] , which conforms to the World Health Organization/Cenlowed to deliver in our animal housing facilities. Infant pups from all litters were randomly distributed among cages, so that each ters for Disease Control and Prevention consensus assay. Samples were preabsorbed with C polysaccharide absorbent (gift of Porter breeder had a litter of 10-12 pups.
Bacteriologic methods. Strains of S. pneumoniae types 3, 19F, Anderson) and calculated versus the US standard reference serum 89SF (Center for Biological Evaluation and Review, US Food and and 23F were stored in Todd-Hewitt broth supplemented with 0.5% yeast extract (Difco, Detroit) and 20% glycerol at 070ЊC.
Drug Administration) assigned 13.0 mg/mL. Type 3 assays were slightly modified, using a coating of methylated human serum Inocula for intranasal challenge were prepared by growing S. pneumoniae to mid-log phase in 10 mL of Todd-Hewitt broth supplealbumin and type 3 pneumococcal polysaccharide at 4ЊC [6] . The standard 89SF was assigned 4.0 mg/mL IgG anti-type 3 polysacmented with 0.5% yeast extract. Bacteria were diluted in 0.5% low-gelling-point agarose to the desired inoculum concentration charide using this method. Using these methods, the concentration of anti-type 19 polysaccharide in BPIG was 231 mg/mL and the and briefly stored on ice until intranasal inoculation.
Nasopharyngeal cultures were performed on 5% sheep blood concentration of anti-type 3 polysaccharide was 72 mg/mL. The lower limit of detection in sera was 0.1 mg/mL for both serotypes. agar supplemented with 2.5 mg/L gentamicin (Becton Dickinson Microbiology Systems, Cockeysville, MD). Plates were incubated Statistical methods. The differences in colonization frequency between saline-and BPIG-treated infant rats and the proportion overnight at 37ЊC, and colonies were counted 24 h later. S. pneumoniae was identified by colonial morphology and, when necesof animals with light and heavy colonization were compared using Fisher's exact test. P õ .05 was considered significant. sary, optochin disk susceptibility.
Animal models. For the intranasal inoculation model, infant rats were randomized to be pretreated with saline or with 10 3 (12 animals/treatment group: saline or 10 or 50 mg of BPIG).
as described previously [4] . BPIG contains ú95% IgG, trace
All animals were heavily colonized (ú50 cfu/10 mL) with S.
amounts of IgM and IgA, and 150 mg/mL nonspecific antibody.
pneumoniae 24 h later. In another experiment, 24 infant rats were
At 24 h later, each infant rat was challenged with 10 mL of S.
intranasally inoculated with a lower inoculum (6 1 10 3 cfu) of Intralitter colonization model with type 3 S. pneumoniae. was defined as at least 1 cfu of S. pneumoniae per 10 mL of nasal Eight cages were studied. A total of 38 infant rats were treated fluid. Recovery of £50 and ú50 cfu/10 mL was considered light with 50 mg of BPIG, and 37 were treated with saline 1 day and heavy colonization, respectively. before inoculation of the index animals. All 16 index animals treated animals than the BPIG-treated animals on days 6 -10 with S. pneumoniae, and 9 (36%) had light colonization; conversely, 3 (25%) of 12 colonized BPIG-treated animals were (P õ .05 at all time points; figure 1). On day 10, 35 (92%) of 38 animals were colonized in the saline-treated group verheavily colonized, whereas the remaining 9 had light colonization (P Å .04). Similar results were found on days 8 and 10 sus 18 (49%) of 37 in the BPIG-treated group (P õ .001, relative risk Å 0.53, 95% confidence interval Å 0.37 -0.74).
(P õ .05; figure 2 ). In BPIG-treated animals, the geometric mean type 3 anticapWhen only colonized animals were analyzed, the percentage of heavily colonized (ú50 cfu/10 mL) animals on days 6 -10 sular antibody concentration from pooled blood on day 1 was 8.22 mg/mL and on day 7 was 1.44 mg/mL. No type 3 anticapwas significantly higher in saline-treated than in BPIG-treated animals (P õ .05; figure 2 ). On day 6, for example, 16 (64%) sular antibody was detected in saline-treated contact animals on days 1 or 7 (õ0.1 mg/mL). of 25 colonized saline-treated animals were heavily colonized gate Hib vaccine elicited much higher serum antibody concentrations (11.8 -66.7 mg/mL after booster doses) and reduced Four cages were studied: 20 animals received 50 mg of BPIG, colonization [11, 12] . Prevention of nasopharyngeal colonizaand 18 received saline. On day 10, 6 of 20 of the BPIG-treated tion may therefore be dependent on higher serum concentraanimals versus 14 of 18 saline-treated animals were colonized tions. with S. pneumoniae type 19F (P Å .05). No difference in the Reduction of nasal carriage of S. pneumoniae may also be density of colonization was noted between BPIG-and salinerelated to serum concentrations of antipneumococcal antibody. treated animals. In BPIG-treated animals, the geometric mean Unlike polysaccharide pneumococcal vaccines, a heptavalent type 19F anticapsular antibody concentration from pooled conjugate pneumococcal vaccine significantly reduced nasophablood on day 1 was 18.0 mg/mL. No type 19F anticapsular ryngeal carriage of vaccine-type pneumococci after 2 doses of antibody was detected in saline-treated contact animals on day vaccine in children [13] . Although S. pneumoniae type 3 is not 1 (õ0.1 mg/mL).
included in current conjugate vaccines, it is notable that the serum concentrations of antibody that resulted in reduced colonization Discussion with serotype 3 in the intralitter model were similar to concentrations achieved for other serotypes following two or three doses In this study, we evaluated systemic pneumococcal anticapof conjugate pneumococcal vaccines [13, 14] . sular antibody for prevention of nasal colonization with S.
The intralitter model of S. pneumoniae colonization has some pneumoniae in the infant rat. In our direct intranasal inoculation limitations. First, serum concentrations of passively adminismodel, no reduction in the frequency or density of nasal colonitered antibody diminish rapidly over time. In infant rats, accelzation with S. pneumoniae type 3 or 23F occurred after treaterated clearance of human antibody occurs after 7 days, either ment with anticapsular antibody. In contrast, in the intralitter as a result of stimulation of anti -human IgG antibody or betransmission model, systemic pneumococcal anticapsular anticause of antibody neutralization by capsular antigen at mucosal body provided significant protection from acquisition of S.
sites [15] . Using our model, it may be difficult to determine a pneumoniae type 3 and 19F. At the serum concentrations minimum protective serum antibody concentration from pasachieved, anticapsular antibody reduced the frequency of colosive immunization experiments, as this model may underestinization almost 2-fold. Furthermore, in colonized animals, mate the protective effect of anticapsular antibodies in humans. anticapsular antibody also effectively reduced the concentraSecond, conjugate vaccines may reduce colonization by both tions of S. pneumoniae type 3 in nasal washes in BPIG-treated mucosal and systemic immunologic responses. Both secretory animals compared with that in saline-treated animals. These IgA -and serum-derived IgG, for example, are detectable in results suggest that systemic anticapsular antibody protects the saliva of children after administration of conjugate Hib against intralitter spread of mucosal colonization with S. pneuvaccine [3] . Our model does not address the contribution of moniae.
secretory IgA in the prevention of nasal colonization with S. Previous animal models that have been studied to evaluate pneumoniae. Additionally, we used passive immunization with S. pneumoniae colonization have relied primarily on direct immune globulin derived from donors immunized with pure inoculation of mucosal surfaces in CBA/N mice and in chinpolysaccharide pneumococcal vaccine. Therefore, issues such chillas [7, 8] . These models require a relatively large inoculum as boosting and antibody subclass production following immu-(10 3 -10 7 cfu) and thus may not adequately reflect the condinization with conjugate pneumococcal vaccines could not be tions of colonization in humans. In contrast, in our infant rat addressed in this passive immunization model. Finally, it is intralitter transmission model, acquisition of colonization reuncertain whether our findings with S. pneumoniae types 3 and sulted from contact with other colonized animals. This model 19F would apply to other pneumococcal serotypes. may thus have greater relevance to the acquisition of S. pneuOur study demonstrates that systemic IgG antibody to pneumoniae colonization in humans.
mococcal polysaccharide reduces the intralitter transmission of In animal models of Hib infection, the capacity of systemic S. pneumoniae types 3 and 19F. Therefore, IgG antibodies may antibodies to prevent colonization has been investigated. In be sufficient to reduce pneumococcal nasopharyngeal carriage an intralitter transmission model, passively administered burro in humans. This suggests that the phenomenon of herd immuantibody to Hib did not protect against nasopharyngeal coloninity may occur after mass immunization with a conjugate pneuzation, although antibody levels were not measured [9] . Conmococcal vaccine, and has important ramifications for children versely, serum concentrations of human anti -Hib antibody ú7 in day care or those exposed to infected persons. This model mg/mL prevented nasal colonization in an infant rat model could serve to study potential vaccine candidates, such as pneu- [3] . These conflicting results may be due to different systemic mococcal proteins, and establish whether these vaccines would antibody concentrations achieved in each study. Human studies protect against nasopharyngeal carriage. of nasopharyngeal colonization with Hib provide further evidence for the role of serum antibodies in preventing coloniza-
